Any current/future new fundraising through debt or equity?

No immediate plans to raise funds through equity or debt for the upcoming 5,000-bed expansion. The company currently has a strong cash position and room for additional debt if required. Internal accruals and cash flow conversion are expected to fund future capex and expansions. Some debt will be taken going forward, but no specific fundraising plan announced for this. Debt level as of now stands at around INR 230 crores with net debt at INR 116 crores. The company aims to maintain steady margins and strong financial health without significant dilution or overleveraging.

Any current/future capex/capital investment/strategic investment?

Greater Noida and Noida Extension brownfield expansions are underway, with basic construction started for Greater Noida and legal formalities completed for both. Capex per bed for brownfield expansions is around INR 75 lakhs (excluding land), with no expected cost escalation. Plans to add 5,000 beds over the next three years, with 70% coming from acquisitions and 30% through greenfield projects. Focus on acquiring hospitals in well-understood geographies (NCR, major North Indian cities). Capex and expansions will be primarily funded through internal accruals and manageable debt; no immediate p

Future growth expectations in sales/revenue/volumes?

Expect to surpass FY '26 revenue growth of 36% in FY '27, driven by ramp-up of new hospitals and acquisitions. New facilities like New Delhi and Faridabad hospitals, plus acquisitions such as Agra, are contributing to revenue growth. Full-year impact of CGHS rate revisions (5% revenue increase) will be realized in FY '27, boosting revenues. Oncology revenue is expected to continue growing, supported by new oncology teams and services. Expansion plans include brownfield projects in Greater Noida and Noida Extension, with ongoing construction and planned capacity increases. Upcoming Gurugram hos

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to surpass the current year's growth of 36% YoY revenue growth in FY '27. Consolidated EBITDA margin guidance is maintained at 24%-25%, with potential for improvement in FY '27. Adjusted EBITDA margins for FY '26 were strong at 28.5%, showing operating leverage and improved mix. New hospitals are ramping up fast, with break-even expected in H2 FY '27 for New Delhi and Faridabad units. The Agra hospital is already profitable with an 18% EBITDA margin. ARPOB (Average Revenue Per Occupied Bed) is expected to grow around 10% annually due to improved specialty mix and higher con

IN US

Sale is live|00:00:00left today

Yatharth Hospital & Trauma Care Services LtdQ1 FY26Healthcare Services

Yatharth Hospital & Trauma Care Services Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹837P/E: 47.0Market Cap: ₹7.9K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Expect to surpass FY '26 revenue growth of 36% in FY '27, driven by ramp-up of new hospitals and acquisitions.
→New facilities like New Delhi and Faridabad hospitals, plus acquisitions such as Agra, are contributing to revenue growth.
→Full-year impact of CGHS rate revisions (5% revenue increase) will be realized in FY '27, boosting revenues.
→Oncology revenue is expected to continue growing, supported by new oncology teams and services.
→Expansion plans include brownfield projects in Greater Noida and Noida Extension, with ongoing construction and planned capacity increases.
→Upcoming Gurugram hospital expected operational in 13-15 months, contributing to growth and targeting EBITDA breakeven within 15 months.
→Focus on specialty mix (tertiary and quaternary care) and self-pay/insurance business to enhance revenue quality.
→Target of 5,000 beds over next three years, possibly achieved earlier, through ~70% acquisitions and ~30% greenfield expansions.

Margin guidance

Category 3

→The company expects to surpass the current year's growth of 36% YoY revenue growth in FY '27.
→Consolidated EBITDA margin guidance is maintained at 24%-25%, with potential for improvement in FY '27.
→Adjusted EBITDA margins for FY '26 were strong at 28.5%, showing operating leverage and improved mix.
→New hospitals are ramping up fast, with break-even expected in H2 FY '27 for New Delhi and Faridabad units.
→The Agra hospital is already profitable with an 18% EBITDA margin.
→ARPOB (Average Revenue Per Occupied Bed) is expected to grow around 10% annually due to improved specialty mix and higher contribution from private insurance, cash, and international patients.
→Operating efficiencies, higher realizations, and specialty expansion will further drive profitability and earnings growth.
→Profit after tax for FY '26 grew 30% YoY, affirming strong earnings momentum.

3 more insights locked — sign up free to unlock

Fundraise plans

→No immediate plans to raise funds through equity or debt for the upcoming 5,000-bed expansion.
→The company currently has a strong cash position and room for additional debt if required.
→Internal accruals and cash flow conversion are expected to fund future capex and expansions.
→Some debt will be taken going forward, but no specific fundraising plan announced for this.
→Debt level as of now stands at around INR 230 crores with net debt at INR 116 crores.
→The company aims to maintain steady margins and strong financial health without significant dilution or overleveraging.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Yatharth Hospital & Trauma Care Services Limited. However, relevant expansion and acquisition plans indicating future business momentum include: - Target to surpass 5,000 beds in the next three years, possibly earlier. - 3,200 beds already announced over the existing 2,500 beds. - Bed additions split as approximately 70% acquisitions and 30% greenfield projects. - Ongoing brownfield expansion for Greater Noida and Noida Extension, with construction work started. - New hospitals in Faridabad and Delhi expected to break even in next 12-15 months. - Capex for brownfield expansions around INR 75 lakhs per bed, with no expected cost escalation. - Strong pipeline of acquisitions focused on strategic locations in NCR and North India. No specific order book or sales pipeline numbers were disclosed in the transcript.

Capex plans

Yes

→Greater Noida and Noida Extension brownfield expansions are underway, with basic construction started for Greater Noida and legal formalities completed for both.
→Capex per bed for brownfield expansions is around INR 75 lakhs (excluding land), with no expected cost escalation.
→Plans to add 5,000 beds over the next three years, with 70% coming from acquisitions and 30% through greenfield projects.
→Focus on acquiring hospitals in well-understood geographies (NCR, major North Indian cities).
→Capex and expansions will be primarily funded through internal accruals and manageable debt; no immediate plans for external fundraising.
→Seeding new clusters such as Gurugram with a hospital to expand presence.
→Emphasis on operationalizing acquired assets promptly to surpass bed capacity targets earlier than planned.

How does Yatharth Hospital & Trauma Care Services Ltd rank vs peers in Healthcare Services?

Pro feature

1Yatharth Hospital & Trauma Care Services Ltd

Rev 2Mar 3

See full Healthcare Services sector rankings

Want more stocks like Yatharth Hospital & Trauma Care Services Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio